1. Sanofi's Lunsekimig Clears Phase 2 Hurdles in Asthma and CRSwNP Trials
Sanofi's investigational drug lunsekimig has successfully met both its primary and key secondary endpoints in two separate Phase 2 clinical trials, signaling a significant step forward for the biopharma giant's pipeline. The trials evaluated the drug's efficacy and safety in treating patients with asthma and chronic rh...